Shopping Cart 0
Cart Subtotal
USD 0

Global Contraceptives Market: Drivers, Opportunities, Trends and Forecast 2017-2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Contraceptives Market-Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Birth control has a broad positive impact and has expanded opportunities for women in terms of economic advancements, educational attainment, and improved health outcomes. A contraceptive helps individuals and couples to gain basic right and is a right to decide when and how many children to have. The rising adoption of traditional and modern methods of contraception has resulted in the improvement not only in health-related outcomes but in several economic and social issues. For instance, it has reduced the infant mortality and maternal mortality rates. According to Centers for Disease Control and Prevention (CDC), the introduction toward access to modern contraceptives is among one of the 10 great public health achievements of the 20th century.

The implementation of modern contraceptive methods offers safe provision by eliminating unwanted restrictive practices and medical barriers. The WHO has developed a set of medical eligibility criteria that is based on a collaborative review of all clinical, research, epidemiological, and modern contraceptive methods.

The major products in the market include:

Yasmin and Yaz (oral pills)

NuvaRing (Vaginal Ring)

Milex Wide Seal (Diaphragm)

Mirena and ParaGard (IUDs)

Ortho Evra (or Evra patch)

Implanon (implant)

The market is dominated by Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, and Church & Dwight, which has more than 65% to 75% market share in the Global Contraceptives Market. Factors, such as an increase in the incidence of unwanted pregnancies, rise in the adoption of oral pills and its advantages over other contraceptives, the unmet need for contraception in developing countries, growing awareness and initiatives taken by governments to prevent unwanted pregnancies, are expected to boost the market growth.

Market Analysis: The Global Contraceptives Market is estimated to witness a CAGR of 4.3% during the forecast period 2017-2023. The market is analyzed based on three segments, namely product type, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the contraceptives market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to the highest proportion of young women who need to use modern contraceptives methods. Further, the government is focusing toward improvising healthcare infrastructure and creating awareness among people for early prevention of unintended pregnancies. However, the healthcare expenditure in most of the developing countries have saved millions of dollars by adopting contraceptives, especially oral pills.

The government in most of the developing countries are taking initiatives for creating awareness about contraceptives by conducting programs and collaborating with NGOs to have an effective spread of contraceptives in order to reduce poverty and illiteracy caused due to unplanned births. It is encouraging the use of condoms by supplying them door to door and imparting knowledge to prevent the spread of STDs and restrict population growth. However, few rural areas, and cultural and religious opposition in certain emerging countries, such as China, India, Thailand, Vietnam, Malaysia, and Philippines, hinder the market growth.

Product Analysis: Contraceptive drugs are growing at a moderate rate and dominates the global contraceptives market with 62% of the total market share. Factors, such as rise in prevalence of unwanted pregnancies, rise in adoption of oral pills and its advantages over other contraceptives, and government initiatives, are driving the market growth. Contraceptive drugs are most frequently used for birth control and is widely adopted among young couples and career-oriented professional women. Contraceptive devices play an important role in saving individuals from getting STDs, preventing unwanted pregnancies, and help in family planning. The contraceptive devices market is estimated to be USD 10.5 billion in 2016 and is expected to reach USD 15.6 billion by 2023, growing at a CAGR of 5.7% during the forecast period, 2016-2023.

Key Players: Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.

Competitive Analysis: The global contraceptives market has immense growth opportunities for vendors in both developed and developing regions. The market in the developed countries is seeing an increase in the adoption of modern contraceptives, especially in the US, Canada, France, Germany, the UK, and few of the Middle East countries. These countries have the highest number of frequent user population accounting to 70% to 75% of the total contraceptive population worldwide.

Pharmaceutical companies are the leading vendors in the market and have major competition with other vendors for the use of contraceptives. The market has substantial potential to gain attention of several new vendors in developing countries, thereby intensifying the competition. The vendors have strong focus on understanding the customer base by creating awareness and initiatives to generate knowledge about their products and upcoming technologically-advanced contraceptives. The growing awareness about the products and a rise in the number of physician-owned implant distributions that have resulted in an increase in the volume of contraceptive procedures have led individuals undergo implantation of contraceptive devices.

Benefits: The report provides complete details about the usage and adoption rate of contraceptives for birth control, family planning, and to avoid unwanted pregnancies. Therefore, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives toward contraceptive adoption in the upcoming years. They can also get details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

READ MORE

Table Of Content

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Industry Trends 13

2 Report Outline 16

2.1 Report Scope 16

2.2 Report Summary 16

2.3 Research Methodology 17

2.4 Report Assumptions 17

3 Market Snapshot 18

3.1 Total Addressable Market (TAM) 18

3.2 Segmented Addressable Market (SAM) 20

3.3 Related Markets 20

4 Market Outlook 21

4.1 Overview 21

4.2 Porter 5 (Five) Forces 23

4.3 Market Segmentation 24

4.4 Market Dynamics 24

4.4.1 Drivers 25

4.4.1.1 Growing incidence of unwanted pregnancies 25

4.4.1.2 Increase in prevalence of contraception 25

4.4.1.3 Rise in adoption of oral pills and its advantages over other contraceptives 26

4.4.1.4 Government initiatives 27

4.4.1.5 Unmet need for contraception in developing countries 27

4.4.2 Restraints 28

4.4.2.1 Prolonged regulatory approvals of contraceptives 28

4.4.2.2 Cultural and religious opposition 28

4.4.2.1 Availability of low cost generic contraceptives 28

4.4.2.2 Limited knowledge about modern contraceptives 28

4.4.2.3 Intense competition among vendors 29

4.4.3 Opportunities 29

4.4.3.1 Technological advancements 29

4.4.3.2 Rise in effective awareness programs 30

4.4.3.3 High demand of cheap contraceptives 30

4.4.3.4 Increase in mergers and acquisition 30

4.4.3.5 Increase in healthcare spending 30

4.4.4 DRO-Impact Analysis 31

4.4.5 Key Stakeholders 32

5 Market Segmentation by Product Types: Market Size & Analysis 32

5.1 Overview 32

5.1.1 Market Size and Analysis 32

5.2 Contraceptive Drugs Market 35

5.3 Contraceptive Devices Market 37

5.4 Global Condom Market 39

5.4.1 Global IUD Market 39

5.4.1.1 Overview 39

5.4.2 Global sub-dermal Implants 40

5.4.2.1 Overview 40

5.4.3 Global Vaginal Rings Market 41

5.4.3.1 Overview 41

5.4.4 Global Non-Surgical Permanent Contraceptive Market 41

5.4.4.1 Overview 41

5.4.5 Global Diaphragms Market 42

5.4.5.1 Overview 42

5.4.6 Global Sponges Market 42

5.4.6.1 Overview 44

6 Regions: Market Size & Analysis 45

6.1 North America 46

6.1.1 Market Overview 46

6.2 Europe 47

6.2.1 Market Overview 47

6.3 APAC 49

6.3.1 Market Overview 49

6.4 Rest of the World 50

6.4.1 Market Overview 50

7 Competitive Landscape 53

7.1 Competitor Comparison Analysis 53

8 Vendor Profiles 55

8.1.1 Allergan plc 55

8.1.1.1 Overview 55

8.1.1.2 Business unit 58

8.1.1.3 Business focus 59

8.1.1.4 SWOT analysis 59

8.1.1.5 Business strategies 60

8.1.2 Bayer AG 61

8.1.2.1 Overview 61

8.1.2.2 Business unit 63

8.1.2.3 Business focus 64

8.1.2.4 SWOT analysis 65

8.1.2.5 Business strategies 66

8.1.3 Merck & Co., Inc. 66

8.1.3.1 Overview 66

8.1.3.2 Business unit 68

8.1.3.3 Business focus 69

8.1.3.4 SWOT analysis 69

8.1.3.5 Business strategies 71

8.1.4 Teva Pharmaceutical Industries Ltd 71

8.1.4.1 Overview 71

8.1.4.2 Business unit 74

8.1.4.3 Business focus 75

8.1.4.4 SWOT analysis 75

8.1.4.5 Business strategies 76

8.1.5 Church & Dwight 77

8.1.5.1 Overview 77

8.1.5.2 Business unit 78

8.1.5.3 Business focus 79

8.1.5.4 SWOT analysis 79

8.1.5.5 Business strategies 80

Annexure 81

Acronyms 81

 

 

 

 

 

 

 

 

 

 

 

 

 

 


List Of Figure

Charts

 

CHART 1 CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS 10

CHART 2 PERCENTAGE OF ADOLESCENCE WOMEN AT EACH AGE GROUP IN ALL DEVELOPING REGIONS 2016 10

CHART 3 PERCENTAGE SPLIT OF 252 MILLION WOMEN AGED 15-19 YEARS, 2016 11

CHART 4 PERCENTAGE OF MODERN CONTRACEPTION METHODS USAGE AMONG WOMEN AGED 15 TO 49 YEARS (MARRIED OR IN A UNION), 2015 12

CHART 5 NUMBER OF MARRIED OR IN UNION WOMEN USING CONTRACEPTION (MILLIONS), IN 2015 13

CHART 6 DEVELOPMENTS IN CONTRACEPTIVE METHODS 13

CHART 8 RESEARCH METHODOLOGY 17

CHART 9 GLOBAL MEDICAL INDUSTRY SEGMENTATION 19

CHART 10 MEDICAL ELIGIBILITY BY CATEGORIES 21

CHART 11 GLOBAL CONTRACEPTIVES MARKET REVENUE, 2016-2023 (USD MILLION) 22

CHART 12 PORTERS 5 FORCES ON CONTRACEPTIVES MARKET 22

CHART 13 CONTRACEPTIVES MARKET SEGMENTATION 23

CHART 14 MARKET DYNAMICS-DRIVERS, RESTRAINTS, AND OPPORTUNITIES 25

CHART 15 GLOBAL CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS, 2015 26

CHART 16 THE PERCENTAGE OF THOSE WHO LIMIT BIRTH IS TWICE AS HIGH IN SOUTH CENTRAL ASIA AND SOUTHEAST ASIA WHEN COMPARED TO THOSE WOMEN IN SUB-SAHARAN AFRICA. 27

CHART 17 DRO-IMPACT ANALYSIS OF IOT HEALTHCARE MARKET 32

CHART 18 KEY STAKEHOLDERS 33

CHART 19 CONTRACEPTIVES MARKET SEGMENTATION BY PRODUCT TYPE, 2016 33

CHART 20 CONTRACEPTIVES MARKET REVENUE BY TYPE, 2016-2023 (USD MILLION) 34

CHART 21 PERCENTAGE SPLIT OF CONTRACEPTIVE MARKET 2016 35

CHART 22 CONTRACEPTIVE DRUGS MARKET SEGMENTATION 2016 36

CHART 23 CONTRACEPTIVES DRUGS MARKET REVENUE, 2016-2023 37

CHART 24 CONTRACEPTIVE DEVICES MARKET REVENUE, 2016-2023 (USD MILLION) 38

CHART 25 CONTACEPTIVE DEVICES MARKET SEGMENTATTION 2016 38

CHART 26 CONTRACEPTIVE DEVICES SEGMENTATION 2016 (% SHARE) 39

CHART 27 GLOBAL CONDOM MARKET REVENUE, 2016-2023 (USD MILLION) 40

CHART 28 GLOBAL IUD MARKET REVENUE, 2016-2023 (USD MILLION) 40

CHART 29 GLOBAL SUB-DERMAL IMPLANTS MARKET REVENUE, 2016-2023 (USD MILLION) 41

CHART 30 GLOBAL VAGINAL RINGS MARKET REVENUE, 2016-2023 (USD MILLION) 42

CHART 31 GLOBAL NON-SURGICAL PERMANENT CONTRACEPTIVE MARKET REVENUE, 2016-2023 (USD MILLION) 42

CHART 32 GLOBAL DIAPHRAGMS MARKET REVENUE, 2016-2023 (USD MILLION) 43

CHART 33 GLOBAL SPONGES MARKET REVENUE, 2016-2023 (USD MILLION) 44

CHART 34 GLOBAL CONTRACEPTIVES MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 AND 2023 (% SHARE) 45

CHART 35 GLOBAL CONTRACEPTIVES MARKET OVERVIEW BY REGIONS 2016 (USD MILLION) 45

CHART 36 CONTRACEPTIVES MARKET REVENUE IN NORTH AMERICA, 2016-2023 (USD MILLION) 46

CHART 37 CONTRACEPTIVES MARKET REVENUE IN THE EUROPE, 2016-2023 (USD MILLION) 48

CHART 38 CONTRACEPTIVES MARKET REVENUE IN APAC, 2016-2023 (USD MILLION) 49

CHART 39 CONTRACEPTIVES MARKET REVENUE IN THE REST OF THE WORLD, 2016-2023 (USD MILLION) 51

CHART 40 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 (USD MILLION) 52

CHART 41 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 (% SHARE) 52

CHART 42 ALLERGAN PLC: OVERVIEW SNAPSHOT 57

CHART 43 ALLERGAN PLC: BUSINESS UNITS 58

CHART 44 ALLERGAN PLC: SWOT ANALYSIS 59

CHART 45 BAYER AG: OVERVIEW SNAPSHOT 62

CHART 46 BAYER AG: BUSINESS UNITS 63

CHART 47 BAYER AG: SWOT ANALYSIS 64

CHART 48 CHURCH & DWIGHT CO., INC.: OVERVIEW SNAPSHOT 66

CHART 49 CHURCH & DWIGHT CO., INC.: BUSINESS UNITS 67

CHART 50 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS 68

CHART 51 MERCK & CO: OVERVIEW SNAPSHOT 70

CHART 52 MERCK & CO: BUSINESS UNITS 71

CHART 53 MERCK & CO: SWOT ANALYSIS 72

CHART 54 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 74

CHART 55 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 76

CHART 56 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 77

 


List Of Table

TABLE 1 CONTRACEPTIVE MARKET REVENUE BY TYPE, 2016-2023 (USD BILLION) 35

TABLE 2 GLOBAL CONTRACEPTIVES MARKET REVENUE BY REGIONS FORECAST, 2016-2023 (USD MILLION) 46

TABLE 3 DRO (NORTH AMERICA) 47

TABLE 4 DRO (EUROPE) 48

TABLE 5 DRO (APAC) 50

TABLE 6 DRO (REST OF THE WORLD) 51

TABLE 1 ALLERGAN PLC: PRODUCT OFFERINGS 55

TABLE 2 ALLERGAN PLC: RECENT DEVELOPMENTS 55

TABLE 3 BAYER AG: PRODUCT OFFERINGS 61

TABLE 4 BAYER AG: RECENT DEVELOPMENTS 61

TABLE 5 CHURCH & DWIGHT CO., INC.: PRODUCT OFFERINGS 65

TABLE 6 CHURCH & DWIGHT CO., INC.: RECENT DEVELOPMENTS 65

TABLE 7 MERCK & CO: PRODUCT OFFERINGS 69

TABLE 8 MERCK & CO: RECENT DEVELOPMENTS 70

TABLE 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 74

TABLE 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 74

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.

Global Contraceptives Market-Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Birth control has a broad positive impact and has expanded opportunities for women in terms of economic advancements, educational attainment, and improved health outcomes. A contraceptive helps individuals and couples to gain basic right and is a right to decide when and how many children to have. The rising adoption of traditional and modern methods of contraception has resulted in the improvement not only in health-related outcomes but in several economic and social issues. For instance, it has reduced the infant mortality and maternal mortality rates. According to Centers for Disease Control and Prevention (CDC), the introduction toward access to modern contraceptives is among one of the 10 great public health achievements of the 20th century.

The implementation of modern contraceptive methods offers safe provision by eliminating unwanted restrictive practices and medical barriers. The WHO has developed a set of medical eligibility criteria that is based on a collaborative review of all clinical, research, epidemiological, and modern contraceptive methods.

The major products in the market include:

Yasmin and Yaz (oral pills)

NuvaRing (Vaginal Ring)

Milex Wide Seal (Diaphragm)

Mirena and ParaGard (IUDs)

Ortho Evra (or Evra patch)

Implanon (implant)

The market is dominated by Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, and Church & Dwight, which has more than 65% to 75% market share in the Global Contraceptives Market. Factors, such as an increase in the incidence of unwanted pregnancies, rise in the adoption of oral pills and its advantages over other contraceptives, the unmet need for contraception in developing countries, growing awareness and initiatives taken by governments to prevent unwanted pregnancies, are expected to boost the market growth.

Market Analysis: The Global Contraceptives Market is estimated to witness a CAGR of 4.3% during the forecast period 2017-2023. The market is analyzed based on three segments, namely product type, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the contraceptives market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to the highest proportion of young women who need to use modern contraceptives methods. Further, the government is focusing toward improvising healthcare infrastructure and creating awareness among people for early prevention of unintended pregnancies. However, the healthcare expenditure in most of the developing countries have saved millions of dollars by adopting contraceptives, especially oral pills.

The government in most of the developing countries are taking initiatives for creating awareness about contraceptives by conducting programs and collaborating with NGOs to have an effective spread of contraceptives in order to reduce poverty and illiteracy caused due to unplanned births. It is encouraging the use of condoms by supplying them door to door and imparting knowledge to prevent the spread of STDs and restrict population growth. However, few rural areas, and cultural and religious opposition in certain emerging countries, such as China, India, Thailand, Vietnam, Malaysia, and Philippines, hinder the market growth.

Product Analysis: Contraceptive drugs are growing at a moderate rate and dominates the global contraceptives market with 62% of the total market share. Factors, such as rise in prevalence of unwanted pregnancies, rise in adoption of oral pills and its advantages over other contraceptives, and government initiatives, are driving the market growth. Contraceptive drugs are most frequently used for birth control and is widely adopted among young couples and career-oriented professional women. Contraceptive devices play an important role in saving individuals from getting STDs, preventing unwanted pregnancies, and help in family planning. The contraceptive devices market is estimated to be USD 10.5 billion in 2016 and is expected to reach USD 15.6 billion by 2023, growing at a CAGR of 5.7% during the forecast period, 2016-2023.

Key Players: Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.

Competitive Analysis: The global contraceptives market has immense growth opportunities for vendors in both developed and developing regions. The market in the developed countries is seeing an increase in the adoption of modern contraceptives, especially in the US, Canada, France, Germany, the UK, and few of the Middle East countries. These countries have the highest number of frequent user population accounting to 70% to 75% of the total contraceptive population worldwide.

Pharmaceutical companies are the leading vendors in the market and have major competition with other vendors for the use of contraceptives. The market has substantial potential to gain attention of several new vendors in developing countries, thereby intensifying the competition. The vendors have strong focus on understanding the customer base by creating awareness and initiatives to generate knowledge about their products and upcoming technologically-advanced contraceptives. The growing awareness about the products and a rise in the number of physician-owned implant distributions that have resulted in an increase in the volume of contraceptive procedures have led individuals undergo implantation of contraceptive devices.

Benefits: The report provides complete details about the usage and adoption rate of contraceptives for birth control, family planning, and to avoid unwanted pregnancies. Therefore, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives toward contraceptive adoption in the upcoming years. They can also get details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

READ MORE

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Industry Trends 13

2 Report Outline 16

2.1 Report Scope 16

2.2 Report Summary 16

2.3 Research Methodology 17

2.4 Report Assumptions 17

3 Market Snapshot 18

3.1 Total Addressable Market (TAM) 18

3.2 Segmented Addressable Market (SAM) 20

3.3 Related Markets 20

4 Market Outlook 21

4.1 Overview 21

4.2 Porter 5 (Five) Forces 23

4.3 Market Segmentation 24

4.4 Market Dynamics 24

4.4.1 Drivers 25

4.4.1.1 Growing incidence of unwanted pregnancies 25

4.4.1.2 Increase in prevalence of contraception 25

4.4.1.3 Rise in adoption of oral pills and its advantages over other contraceptives 26

4.4.1.4 Government initiatives 27

4.4.1.5 Unmet need for contraception in developing countries 27

4.4.2 Restraints 28

4.4.2.1 Prolonged regulatory approvals of contraceptives 28

4.4.2.2 Cultural and religious opposition 28

4.4.2.1 Availability of low cost generic contraceptives 28

4.4.2.2 Limited knowledge about modern contraceptives 28

4.4.2.3 Intense competition among vendors 29

4.4.3 Opportunities 29

4.4.3.1 Technological advancements 29

4.4.3.2 Rise in effective awareness programs 30

4.4.3.3 High demand of cheap contraceptives 30

4.4.3.4 Increase in mergers and acquisition 30

4.4.3.5 Increase in healthcare spending 30

4.4.4 DRO-Impact Analysis 31

4.4.5 Key Stakeholders 32

5 Market Segmentation by Product Types: Market Size & Analysis 32

5.1 Overview 32

5.1.1 Market Size and Analysis 32

5.2 Contraceptive Drugs Market 35

5.3 Contraceptive Devices Market 37

5.4 Global Condom Market 39

5.4.1 Global IUD Market 39

5.4.1.1 Overview 39

5.4.2 Global sub-dermal Implants 40

5.4.2.1 Overview 40

5.4.3 Global Vaginal Rings Market 41

5.4.3.1 Overview 41

5.4.4 Global Non-Surgical Permanent Contraceptive Market 41

5.4.4.1 Overview 41

5.4.5 Global Diaphragms Market 42

5.4.5.1 Overview 42

5.4.6 Global Sponges Market 42

5.4.6.1 Overview 44

6 Regions: Market Size & Analysis 45

6.1 North America 46

6.1.1 Market Overview 46

6.2 Europe 47

6.2.1 Market Overview 47

6.3 APAC 49

6.3.1 Market Overview 49

6.4 Rest of the World 50

6.4.1 Market Overview 50

7 Competitive Landscape 53

7.1 Competitor Comparison Analysis 53

8 Vendor Profiles 55

8.1.1 Allergan plc 55

8.1.1.1 Overview 55

8.1.1.2 Business unit 58

8.1.1.3 Business focus 59

8.1.1.4 SWOT analysis 59

8.1.1.5 Business strategies 60

8.1.2 Bayer AG 61

8.1.2.1 Overview 61

8.1.2.2 Business unit 63

8.1.2.3 Business focus 64

8.1.2.4 SWOT analysis 65

8.1.2.5 Business strategies 66

8.1.3 Merck & Co., Inc. 66

8.1.3.1 Overview 66

8.1.3.2 Business unit 68

8.1.3.3 Business focus 69

8.1.3.4 SWOT analysis 69

8.1.3.5 Business strategies 71

8.1.4 Teva Pharmaceutical Industries Ltd 71

8.1.4.1 Overview 71

8.1.4.2 Business unit 74

8.1.4.3 Business focus 75

8.1.4.4 SWOT analysis 75

8.1.4.5 Business strategies 76

8.1.5 Church & Dwight 77

8.1.5.1 Overview 77

8.1.5.2 Business unit 78

8.1.5.3 Business focus 79

8.1.5.4 SWOT analysis 79

8.1.5.5 Business strategies 80

Annexure 81

Acronyms 81

 

 

 

 

 

 

 

 

 

 

 

 

 

 


List Of Figure

Charts

 

CHART 1 CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS 10

CHART 2 PERCENTAGE OF ADOLESCENCE WOMEN AT EACH AGE GROUP IN ALL DEVELOPING REGIONS 2016 10

CHART 3 PERCENTAGE SPLIT OF 252 MILLION WOMEN AGED 15-19 YEARS, 2016 11

CHART 4 PERCENTAGE OF MODERN CONTRACEPTION METHODS USAGE AMONG WOMEN AGED 15 TO 49 YEARS (MARRIED OR IN A UNION), 2015 12

CHART 5 NUMBER OF MARRIED OR IN UNION WOMEN USING CONTRACEPTION (MILLIONS), IN 2015 13

CHART 6 DEVELOPMENTS IN CONTRACEPTIVE METHODS 13

CHART 8 RESEARCH METHODOLOGY 17

CHART 9 GLOBAL MEDICAL INDUSTRY SEGMENTATION 19

CHART 10 MEDICAL ELIGIBILITY BY CATEGORIES 21

CHART 11 GLOBAL CONTRACEPTIVES MARKET REVENUE, 2016-2023 (USD MILLION) 22

CHART 12 PORTERS 5 FORCES ON CONTRACEPTIVES MARKET 22

CHART 13 CONTRACEPTIVES MARKET SEGMENTATION 23

CHART 14 MARKET DYNAMICS-DRIVERS, RESTRAINTS, AND OPPORTUNITIES 25

CHART 15 GLOBAL CONTRACEPTIVE PREVALENCE AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS, 2015 26

CHART 16 THE PERCENTAGE OF THOSE WHO LIMIT BIRTH IS TWICE AS HIGH IN SOUTH CENTRAL ASIA AND SOUTHEAST ASIA WHEN COMPARED TO THOSE WOMEN IN SUB-SAHARAN AFRICA. 27

CHART 17 DRO-IMPACT ANALYSIS OF IOT HEALTHCARE MARKET 32

CHART 18 KEY STAKEHOLDERS 33

CHART 19 CONTRACEPTIVES MARKET SEGMENTATION BY PRODUCT TYPE, 2016 33

CHART 20 CONTRACEPTIVES MARKET REVENUE BY TYPE, 2016-2023 (USD MILLION) 34

CHART 21 PERCENTAGE SPLIT OF CONTRACEPTIVE MARKET 2016 35

CHART 22 CONTRACEPTIVE DRUGS MARKET SEGMENTATION 2016 36

CHART 23 CONTRACEPTIVES DRUGS MARKET REVENUE, 2016-2023 37

CHART 24 CONTRACEPTIVE DEVICES MARKET REVENUE, 2016-2023 (USD MILLION) 38

CHART 25 CONTACEPTIVE DEVICES MARKET SEGMENTATTION 2016 38

CHART 26 CONTRACEPTIVE DEVICES SEGMENTATION 2016 (% SHARE) 39

CHART 27 GLOBAL CONDOM MARKET REVENUE, 2016-2023 (USD MILLION) 40

CHART 28 GLOBAL IUD MARKET REVENUE, 2016-2023 (USD MILLION) 40

CHART 29 GLOBAL SUB-DERMAL IMPLANTS MARKET REVENUE, 2016-2023 (USD MILLION) 41

CHART 30 GLOBAL VAGINAL RINGS MARKET REVENUE, 2016-2023 (USD MILLION) 42

CHART 31 GLOBAL NON-SURGICAL PERMANENT CONTRACEPTIVE MARKET REVENUE, 2016-2023 (USD MILLION) 42

CHART 32 GLOBAL DIAPHRAGMS MARKET REVENUE, 2016-2023 (USD MILLION) 43

CHART 33 GLOBAL SPONGES MARKET REVENUE, 2016-2023 (USD MILLION) 44

CHART 34 GLOBAL CONTRACEPTIVES MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 AND 2023 (% SHARE) 45

CHART 35 GLOBAL CONTRACEPTIVES MARKET OVERVIEW BY REGIONS 2016 (USD MILLION) 45

CHART 36 CONTRACEPTIVES MARKET REVENUE IN NORTH AMERICA, 2016-2023 (USD MILLION) 46

CHART 37 CONTRACEPTIVES MARKET REVENUE IN THE EUROPE, 2016-2023 (USD MILLION) 48

CHART 38 CONTRACEPTIVES MARKET REVENUE IN APAC, 2016-2023 (USD MILLION) 49

CHART 39 CONTRACEPTIVES MARKET REVENUE IN THE REST OF THE WORLD, 2016-2023 (USD MILLION) 51

CHART 40 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 (USD MILLION) 52

CHART 41 GLOBAL CONTRACEPTIVES MARKET SEGMENTATION BY GEOGRAPHY, 2016-2023 (% SHARE) 52

CHART 42 ALLERGAN PLC: OVERVIEW SNAPSHOT 57

CHART 43 ALLERGAN PLC: BUSINESS UNITS 58

CHART 44 ALLERGAN PLC: SWOT ANALYSIS 59

CHART 45 BAYER AG: OVERVIEW SNAPSHOT 62

CHART 46 BAYER AG: BUSINESS UNITS 63

CHART 47 BAYER AG: SWOT ANALYSIS 64

CHART 48 CHURCH & DWIGHT CO., INC.: OVERVIEW SNAPSHOT 66

CHART 49 CHURCH & DWIGHT CO., INC.: BUSINESS UNITS 67

CHART 50 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS 68

CHART 51 MERCK & CO: OVERVIEW SNAPSHOT 70

CHART 52 MERCK & CO: BUSINESS UNITS 71

CHART 53 MERCK & CO: SWOT ANALYSIS 72

CHART 54 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 74

CHART 55 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 76

CHART 56 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 77

 


List Of Table

TABLE 1 CONTRACEPTIVE MARKET REVENUE BY TYPE, 2016-2023 (USD BILLION) 35

TABLE 2 GLOBAL CONTRACEPTIVES MARKET REVENUE BY REGIONS FORECAST, 2016-2023 (USD MILLION) 46

TABLE 3 DRO (NORTH AMERICA) 47

TABLE 4 DRO (EUROPE) 48

TABLE 5 DRO (APAC) 50

TABLE 6 DRO (REST OF THE WORLD) 51

TABLE 1 ALLERGAN PLC: PRODUCT OFFERINGS 55

TABLE 2 ALLERGAN PLC: RECENT DEVELOPMENTS 55

TABLE 3 BAYER AG: PRODUCT OFFERINGS 61

TABLE 4 BAYER AG: RECENT DEVELOPMENTS 61

TABLE 5 CHURCH & DWIGHT CO., INC.: PRODUCT OFFERINGS 65

TABLE 6 CHURCH & DWIGHT CO., INC.: RECENT DEVELOPMENTS 65

TABLE 7 MERCK & CO: PRODUCT OFFERINGS 69

TABLE 8 MERCK & CO: RECENT DEVELOPMENTS 70

TABLE 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 74

TABLE 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 74

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.